


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-45. Canceled.

46. (New) A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase which inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:




wherein R<sup>1</sup> and R<sup>3</sup> are each independently selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic.


47. (New) A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase which inhibitor or a pharmaceutically acceptable salt thereof is selected from the group consisting of a compounds recited in Table I as:

number (nb) 20, nb 21, nb 22, nb 23, nb 36, nb 38, nb 44, nb 53, nb 57, nb 58, nb 59, nb 60, nb 65, nb 66, nb 67, nb 75, nb 100, nb 103, nb 104, nb 105, nb 108, nb 118, nb 119, nb 124, nb 125, nb 126, nb 128, nb 140, nb 143, nb 148, nb 151, nb 153, nb 156, nb 157, nb 159, nb 167, nb 168, nb 169, nb 170, nb 172, nb 175, nb 176, nb 178, nb 179, nb 180, nb 181, nb 183, nb 188, nb 189, nb 192, nb 193, nb 253, nb 257, nb 270, nb 283, nb 286, nb 287, nb 297, nb 299, nb 341, nb 343, nb 344, nb 347, nb 354, nb 358, nb 359, nb 360, nb 361, nb 362, nb 375, nb 377, nb 379, nb 380, nb 384, nb 385, nb 411, nb 412, nb 413, nb 425, nb 427, nb 428, nb 429, nb 430, nb 434, nb 435,

nb 437, nb 438, nb 461, nb 463, nb 470, nb 471, nb 473, nb 477, nb 478, nb 479, nb 501, nb 504, nb 508, nb 509, nb 531, nb 533, nb 538, nb 543, nb 544, nb 545, nb 551, nb 556, nb 559, nb 562,



48. (New) A method of reducing hypertension in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase which inhibitor or a pharmaceutically acceptable salt thereof is a compound having a structure of:



wherein  $R^1$  and  $R^3$  are each independently selected from the group consisting of  $C_1$ - $C_{20}$  substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic.

49. (New) A method of reducing hypertension in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor or a pharmaceutically acceptable salt thereof of soluble epoxide hydrolase which inhibitor is selected from the group consisting of a compounds recited in Table I as:

number (nb) 20, nb 21, nb 22, nb 23, nb 36, nb 38, nb 44, nb 53, nb 57, nb 58, nb 59, nb 60, nb 65, nb 66, nb 67, nb 75, nb 100, nb 103, nb 104, nb 105, nb 108, nb 118, nb 119, nb 124, nb 125, nb 126, nb 128, nb 140, nb 143, nb 148, nb 151, nb 153, nb 156, nb 157, nb 159, nb 167, nb 168, nb 169, nb 170, nb 172, nb 175, nb 176, nb 178, nb 179, nb 180, nb 181, nb 183, nb 188, nb 189, nb 192, nb 193, nb 253, nb 257, nb 270, nb 283, nb 286, nb 287, nb 297, nb 299, nb 341, nb 343, nb 344, nb 347, nb 354, nb 358, nb 359, nb 360, nb 361, nb 362, nb 375, nb 377, nb 379, nb 380,

nb 384, nb 385, nb 411, nb 412, nb 413, nb 425, nb 427, nb 428, nb 429, nb 430, nb 434, nb 435,  
nb 437, nb 438, nb 461, nb 463, nb 470, nb 471, nb 473, nb 477, nb 478, nb 479, nb 501, nb 504,  
nb 508, nb 509, nb 531, nb 533, nb 538, nb 543, nb 544, nb 545, nb 551, nb 556, nb 559, nb 562,

